Avillion: Lewis Cameron, an innovative model for clinical development.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Avillion: Lewis Cameron, an innovative model for clinical development.
Released on: July 25, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Lewis Cameron CEO, talks about the companies objective, with a strong focus on helping partners develop their drug candidate by incurring 100% of the clinical and regulatory risks, while Pharma will maintain absolute ownership of and control on commercialising the asset.
  • Summary
  • Transcript
  • Participants
  • Company
Lewis Cameron CEO, talks about the companies objective, with a strong focus on helping partners develop their drug candidate by incurring 100% of the clinical and regulatory risks, while Pharma will maintain absolute ownership of and control on commercialising the asset.
Lewis Cameron CEO, talks about the companies objective, with a strong focus on helping partners develop their drug candidate by incurring 100% of the clinical and regulatory risks, while Pharma will maintain absolute ownership of and control on commercialising the asset.
Lewis Cameron
Avillion
Avillion
Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products. We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to the market. Avillion is staffed with a team of expert professionals with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis. Our offices are in London, United Kingdom, and we are financed by our international investors, Abingworth and Clarus Ventures. Contact Us Today